Vir Biotechnology, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Vir Biotechnology, Inc. (VIR) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2023-02-28
- Vir Biotechnology, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $0.00.
- Vir Biotechnology, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $0.00.
- Vir Biotechnology, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was $0.00.
- Vir Biotechnology, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2019 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |